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Salivary gland tumoursmost often present as painless enlargingmasses.Most are located in the parotid glands andmost are benign.
The principal hurdle in their management lies in the difficulty in distinguishing benign from malignant tumours. Investigations
such as fine needle aspiration cytology and MRI scans provide some useful information, but most cases will require surgical
excision as ameans of coming to a definitive diagnosis. Benign tumours and early low-grademalignancies can be adequately treated
with surgery alone, while more advanced and high-grade tumours with regional lymph node metastasis will require postoperative
radiotherapy. The role of chemotherapy remains largely palliative. This paper highlights some of the more important aspects in
the management of salivary gland tumours.
1. Introduction
Salivary gland tumours are rare andmost cases are referred to
the head and neck clinic. Themajority of these neoplasms are
benign and only 20% are malignant. The annual incidence
of salivary gland cancers ranges from 0.5 to 2 per 100,000
in different parts of the world, with the highest incidence
occurring in Croatia [1]. In the United states, there is a rise in
the incidence of salivary gland cancers; this group accounted
for 6.3% of all head and neck cancers in 1974–1976, as
compared to 8.1% in 1998-1999 [2]. The sex distribution
for salivary gland cancers is equal, and the majority of the
cases arise in the sixth decade [3]. Tumours can occur in both
the major and minor salivary glands. 80% of major salivary
gland tumours occur in the parotid glands, while most minor
salivary tumours are located in the palate [4]. As a general
rule in clinical practice, the smaller the salivary gland is, the
more likely the tumour is malignant. In the parotid glands,
20–25% of the tumours are malignant. This rises to 40% for
the submandibular glands, and more than 90% of sublingual
gland tumours are malignant [5, 6].
The etiological agents of salivary gland cancers remain un-
clear. Whilst most other head and neck cancers are strongly
related to smoking and drinking, these do not play a role
in the salivary glands. Some studies have found that a diet
rich in vitamin C and low in cholesterol may be effective
in preventing salivary gland cancer [7]. On the other hand,
possible risk factors include therapeutic radiation for other
head and neck cancers, occupational exposures in rubber
manufacturing and woodworking, and also employment at
hairdressers or beauty shops [8, 9]. History of previous
cancers, related to Epstein-Barr virus, immunosuppression,
and radiation were also associated with an increased risk of
salivary gland cancer. In a Swedish study, the risk of salivary
gland cancer was increased 4 fold in Hodgkin’s lymphoma
patients [10]. HIV infection was also found to increase the
risk of salivary gland cancers [11].
Salivary gland tumours in the parotid or submandibular
glands usually present as an enlarging mass. This may be
associated with neurological symptoms such as facial nerve
paralysis or pain if the tumour is malignant. Minor salivary
gland tumours present as a submucosal intraoral mass which
subsequently ulcerates. Clinical features suspicious for ma-
lignancy include ipsilateral facial nerve palsy, sudden tumour
growth, pain, tumour fixation to the overlying skin or under-
lying muscle, and cervical lymphadenopathy.
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2. Histology
In both the major and minor salivary glands, the commonest
type of benign tumour is pleomorphic adenoma. Pleomor-
phic adenoma, also called benign mixed tumour, can occur
in the deep lobe of the parotid gland with extension into
the parapharyngeal space, which makes it the commonest
type of parapharyngeal space tumour constituting 40% of
tumours there [12]. Pleomorphic adenomas need to be
managed diligently for its capacity to recur and to undergo
malignant transformation. Capsular rupture and subsequent
tumour spillage during excision is the most important risk
factor for recurrence. The risk of malignant change has been
report to be up to 10%. Features predictive of malignant
change include age, tumour size, a long history of the mass,
submandibular location, and the presence of hyalinized
stroma [13].
For malignant salivary tumour, the commonest type
overall is mucoepidermoid carcinoma. However, if we look
at each salivary gland in turn, several large series have shown
that mucoepidermoid carcinoma is only the commonest
cancer in the parotid glands, comprising around 33% [14,
15]. Adenoid cystic carcinoma is the commonest cancer in
the submandibular and minor salivary glands, making up
42–49% [14, 15]. A review of 45 parotid cancer patients
treated at the author’s institute from 2000 to 2010 also
shows mucoepidermoid carcinoma to be the commonest
type (Table 1).
Mucoepidermoid carcinoma is a distinct histological
type with a wide variation in clinical behavior. As such,
histological grading is particularly important in predicting
the prognosis of this group of patients. The tumour is
classified as of low, intermediate, or high grade based on
various histopathological criteria such as intracystic com-
ponent, neural invasion, necrosis, mitosis, lymphovascular
invasion, and bone invasion [16]. The five-year disease-
free survival for low-grade tumours is reported to be 80–
95%, while that for high-grade tumours is 30–50% [17].
Adenoid cystic carcinoma is a more indolent tumour with a
prolonged disease history. These tumours metastasize quite
early because of their propensity for perineural invasion
and hematological spread, with the lungs being the most
common site. Even with distantmetastases, however, patients
can survive for 15 to 20 years. A review of 50 patients with
adenoid cystic carcinoma actually showed that the location
of salivary gland involved, tumour stage, node positivity, and
perineural invasion did not affect overall survival or local
control [18]. The overall survival rates are 50–90% at five
years and 30–67% at 10 years [19]. Acinic cell carcinoma
is also considered to be a low-grade tumour which seldom
invades the facial nerve. Regional recurrences occur late in
this tumour but 16–20% of patients eventually die of this
cancer [14].
3. Investigations
Radiological investigations are frequently employed in the
workup of a salivary gland tumour. It is used to delineate
the tumour location such as intraglandular or extraglandular
Table 1: Distribution of histological types of parotid cancers treated
in QMH from 2000–2010.
Histology Number (%) (total = 45)
Mucoepidermoid carcinoma 11 (24.4%)
Acinic cell carcinoma 9 (20%)
Salivary duct carcinoma 8 (17.7%)
Carcinoma expleomorphic 4 (8.9%)
Adenoid cystic carcinoma 3 (6.7%)
Others 10 (22.3%)
Figure 1: MRI showing right parotid tumour with extension into
the deep lobe.
and whether it is in the superficial or deep lobe of the
parotid gland, to detect malignant features, to define local
extension and invasion of surrounding tissues, and to detect
regional nodal and systemic metastases. Ultrasound is the
preferred tool for initial assessment of tumours in the
superficial parotid and submandibular gland. Ultrasound
imaging resolution of these superficial structures is excellent
and it does not carry any risk of radiation. It can also be
employed to guide the needle when carrying out fine needle
aspiration cytology (FNAC) to reduce sampling error. For
tumours located deep in the parotid gland or in the minor
salivary glands, CT and MRI are more useful. Comparing
the two modalities, MRI has an edge over CT in predicting
malignancy and is also more sensitive in picking up small
tumours. Benign tumours generally show high signal on
T2-weighted scans, while malignant lesions usually show
intermediate to low signal. MRI is more useful in detecting
deep lobe extension (Figure 1), marrow infiltration, and
perineural spread and involvement of the facial nerve.
MR spectroscopy is employed to differentiate malignant
and benign salivary gland tumours and also to distinguish
Warthin’s tumour from pleomorphic adenoma [20]. The
role of CT is usually limited to evaluation of cortical bone
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involvement and the concurrent presence of calculus disease.
The role of positron emission tomography (PET) in salivary
gland disease is still being evaluated. Characteristically,
Warthin’s tumours and oncocytomas show a strong uptake
of technetium pertechnetate.
Fine needle aspiration cytology (FNAC) is another
investigation frequently used. The diagnostic yield of FNAC
can be quite good with large study series showing sensitivity
up to 85% and specificity up to 99% [21]. However, reports
of other studies are far from ideal, and thus controversy as to
the usefulness of FNAC still persists. It is safe to say that the
role of FNAC mainly lies in preoperative patient counseling
and surgical planning. In the case of a malignant FNAC
result, the patient can be better prepared in terms of the
extent of surgery, higher potential complications, and need
for neck dissection or postoperative radiotherapy.
4. Staging
From 2010 onwards, salivary gland cancers are staged accord-
ing to the Seventh Edition of the American Joint Committee
on Cancer (AJCC) Cancer Staging Manual. The primary
tumour (T) is staged according to size, extraparenchymal
extension, and direct invasion. Regional lymph node (N)
staging is dependent on the size and location of the
metastatic lymph nodes. The detection of distant metastasis
is designated as M1. The overall cancer stage is derived from
the combination of these three factors.
5. Treatment
Surgery is the mainstay of treatment for salivary gland
tumours. In the case of parotid gland tumours, superficial
parotidectomy with facial nerve dissection and preservation
is the standard diagnostic procedure. This operation is also
therapeutic in cases of benign or small malignant tumours
limited to the superficial lobe of the gland. Studies in the past
have found enucleation of benign tumours to be associated
with an unacceptably high chance of tumour recurrence
especially for pleomorphic adenomas [22]. However, several
recent studies have suggested that a more limited resection in
the form of extracapsular dissection where the pleomorphic
adenoma is resected only with a cuff of normal glandular
tissue offers better postoperative cosmetic result and lower
incidence of Frey’s syndrome without an increase in the
incidence of tumour recurrence and facial nerve injury [23–
25]. Recurrence rates with either approach are in the order of
1–3% in the literature [26]. Whether a superficial or limited
partial parotidectomy is carried out, the surgical approach
is similar. A modified Blair’s incision which begins just
anterior to the tragus and then curves posteriorly towards
the mastoid process and then gently turns anteriorly and
inferiorly towards a neck skin crease is used (Figure 2). A
skin flap is then raised anteriorly in the relatively avascular
plane of the superficial musculoaponeurotic system (SMAS)
(Figure 3). The parotid gland is dissected free from the tragus
and sternocleidomastoid muscle in order to expose the main
trunk of the facial nerve as it exits the stylomastoid foramen.
Figure 2: Incision for parotidectomy.
Figure 3: Skin flap raised.
The most consistent landmark used in its identification is
the tympanomastoid suture which can be palpated easily.
The rest of the operation involves dissection of individual
branches of the facial nerve which will end up with removal
of the superficial lobe of the parotid gland (Figure 4).
If the tumour involves the deep lobe of the parotid gland,
a total parotidectomy is the procedure of choice to achieve
adequate tumour clearance. This entails full dissection of
all branches of the facial nerve from the superficial lobe,
followed by delivery of the deep lobe from underneath the
nerve. Total parotidectomy with facial nerve preservation is
also indicated for high-grade malignancies and T3-4 cancers.
In these cases, preoperative MRI is very important in order
to delineate the proximity of the tumour to the internal
carotid artery and skull base [27]. Radical parotidectomy, in
which the facial nerve is sacrificed, is only necessary if the
tumour is enveloping or infiltrating the facial nerve. In such
cases, there is often a degree of facial nerve paralysis evident
preoperatively. After facial nerve resection, the nerve is most
often repaired with an interposition graft from another
nerve. Even in experienced hands, the facial nerve function
rarely recovers fully and only House-Brackmann Grade III
can be achieved.
When dealing with submandibular gland tumours, com-
plete excision of the gland is adequate treatment if the
4 ISRN Otolaryngology
Figure 4: All branches of facial nerve dissected.
Figure 5: Incision for submandibular gland excision.
lesion is small, limited to the gland parenchyma, and also
of benign or low-grade malignant nature. More extensive
tumours require excision of the gland bed and also adjacent
soft tissues similar to a supraomohyoid neck dissection [22].
The standard approach is via a transverse incision placed
two finger-breadths below the mandible (Figure 5) and then
elevation of a subplatysmal flap with careful identification
and protection of the marginal mandibular branch of the
facial nerve. The facial vessels are ligated and the gland is
dissected free from the digastric and mylohyoid muscles
while safeguarding the hypoglossal and lingual nerves. The
gland is finally excised after ligation of the Wharton’s duct
(Figure 6).
Management of the clinically N0 neck in salivary gland
cancer remains a controversial topic. Studies on the long-
term efficacy of various approaches in dealing with N0 neck
are limited. Some advocate neck dissection for every salivary
gland cancer patient, while others choose selective neck
dissection or irradiation of the neck for high-risk cancers
only [28–30]. Because of the small size of these studies, no
single approach has been shown to be superior. Overall,
the risk of regional lymph node metastasis in salivary gland
cancer is low compared to other head and neck cancers
and range from 14–20% [31]. High-risk factors include
high-grade and advanced T-stage tumours, tumours with
extracapsular extension, and presence of preoperative facial
Lingual nerve
Digastric tendon
Figure 6: Gland bed after submandibular gland removal.
Table 2: Indications for postoperative radiotherapy.
Risk factors for locoregional recurrence in salivary gland cancers
Close or positive resection margins
High-grade or undifferentiated tumours
Perineural invasion
Skin or bone invasion
Advanced disease involving facial nerve or deep lobe
Lymph node metastases
Tumour spillage during operation
Unresectable or recurrent tumour
paralysis [32]. As such, elective selective neck dissection may
be recommended in these patients. Elective neck dissection
should also be performed if resection of the primary tumour
is aided by removal of the surrounding lymph nodes. An
exception to this is in the case of adenoid cystic carcinoma
in which the chance of occult lymph node metastasis is
low and elective neck dissection is unlikely to offer any
additional benefit [28]. Selective neck dissection for parotid
gland cancer should include levels IB, II, III, IV, and VA, while
that for submandibular gland cancer should include levels I,
II, and III. For patients with proven nodal metastasis, a full
radical neck dissection should be carried out.
Postoperative radiotherapy has proven benefit in salivary
gland cancer patients at high risk of locoregional recurrence.
Several studies have identified important prognostic factors
(Table 2) and postoperative radiotherapy is recommended
[14, 33].
The different types of radiotherapy for salivary gland
cancer include electrons, electron/photon mix, protons, and
neutrons. Neutron beam radiation therapy has been shown
to be more effective in certain tumour histology especially
adenoid cystic carcinoma [34]. Intensity modulated radi-
ation therapy is a popular technique since it offers conformal
radiation producing steep dose gradient which allows for
excellent tumour coverage while reducing dose to surround-
ing normal tissues. The usual postoperative radiotherapy
dosage ranges from 60 to 70Gy in 2Gy daily fractions [27].
The role of chemotherapy remains to be largely palliative
in treating metastatic, recurrent, or unresectable salivary
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gland cancers. Due to the paucity of these patients, ran-
domized Phase III studies on the use of chemotherapy are
lacking. Cisplatin is currently the single agent most often
used. Combination therapies with cisplatin, 5-fluorouracil,
cyclophosphamide, and doxorubicin have also been studied,
but the response rates are quite variable due to the small
number of patients enrolled [35, 36]. More recently, targeted
therapies have also been studied, and the targets include
epidermal growth factor receptor (EGFR), HER2 protoonco-
gene, c-kit protooncogene, and vascular endothelial growth
factor (VEGF). Thus far, no target therapy agent has been
found to be effective [14].
6. Conclusion
Salivary gland tumours are best managed in specialized
head and neck clinics because of their rarity and need for
thorough workup by a multidisciplinary team of specialists.
Surgery forms the keystone of their management since it
serves both diagnostic and therapeutic purposes. The most
important step is in the surgical planning and preoperative
counseling. Large or deep parotid lobe tumours, and those
suspected to be malignant, should be imaged preferably with
MRI in order to decide on the expected extent of resection
and to determine the potential risk to the facial nerve.
The whole surgical exercise in removing a parotid tumour
revolves around careful identification and preservation of
the facial nerve. Injury to the facial nerve causes significant
morbidity to the quality of life of the patients. Elective
selective neck dissection in clinically N0 salivary gland cancer
is recommended when the primary tumour exhibits high-
risk features. On the same note, postoperative radiotherapy
is useful for tumours at risk of locoregional recurrence.
The role of chemotherapy is as yet not well established and
investigations of targeted therapy are still at an early stage.
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